Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Cassava Sciences (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, has announced it will hold a conference call and webcast on Thursday, November 7th, 2024, at 8:30 a.m. Eastern Time to report its third quarter 2024 results. The audio webcast will be accessible through the company's website and will remain available for replay for 90 days following the event.
Cassava Sciences (Nasdaq: SAVA), un'azienda biotecnologica in fase clinica focalizzata sulla malattia di Alzheimer, ha annunciato che terr脿 una conferenza telefonica e un webcast il gioved矛 7 novembre 2024, alle 8:30 a.m. ora orientale per riportare i risultati del terzo trimestre 2024. Il webcast audio sar脿 accessibile tramite il sito web dell'azienda e rimarr脿 disponibile per la riproduzione per 90 giorni dopo l'evento.
Cassava Sciences (Nasdaq: SAVA), una empresa biotecnol贸gica en fase cl铆nica centrada en la enfermedad de Alzheimer, ha anunciado que llevar谩 a cabo una llamada de conferencia y un webcast el jueves 7 de noviembre de 2024, a las 8:30 a.m. hora del Este para informar sobre sus resultados del tercer trimestre de 2024. El webcast de audio ser谩 accesible a trav茅s del sitio web de la empresa y estar谩 disponible para repetici贸n durante 90 d铆as despu茅s del evento.
旃挫偓氚� 靷澊鞏胳姢(Cassava Sciences, Nasdaq: SAVA)電� 鞎岇笭頃橃澊毹� 氤戩棎 歆戩頃橂姅 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓搿�, 2024雲� 11鞗� 7鞚� 氇╈殧鞚�, 霃欕秬 響滌鞁� 旮办鞙茧 鞓れ爠 8鞁� 30攵�鞐� 2024雲� 3攵勱赴 鞁れ爜鞚� 氤搓碃頃橁赴 鞙勴暅 旎嵓霟办姢 旖� 氚� 鞗轨簮鞀ろ姼毳� 臧滌禍頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞓る敂鞓� 鞗轨簮鞀ろ姼電� 須岇偓 鞗轨偓鞚错姼毳� 韱淀暣 鞝戧芳頃� 靾� 鞛堨溂氅� 鞚措菠韸� 鞚错泟 90鞚� 霃欖晥 雼れ嫓 霌れ潉 靾� 鞛堨姷雼堧嫟.
Cassava Sciences (Nasdaq: SAVA), une entreprise de biotechnologie en phase clinique ax茅e sur la maladie d'Alzheimer, a annonc茅 qu'elle tiendra une conf茅rence t茅l茅phonique et un webcast le jeudi 7 novembre 2024, 脿 8h30, heure de l'Est pour pr茅senter ses r茅sultats du troisi猫me trimestre 2024. Le webcast audio sera accessible via le site web de l'entreprise et restera disponible pour rediffusion pendant 90 jours apr猫s l'茅v茅nement.
Cassava Sciences (Nasdaq: SAVA), ein klinisches Biotech-Unternehmen, das sich auf Alzheimer konzentriert, hat angek眉ndigt, dass es am Donnerstag, den 7. November 2024, um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten wird, um die Ergebnisse des dritten Quartals 2024 zu pr盲sentieren. Der Audio-Webcast wird 眉ber die Unternehmens-Website zug盲nglich sein und bleibt 90 Tage nach der Veranstaltung f眉r eine Wiederholung verf眉gbar.
- None.
- None.
Conference call and webcast to begin at 8:30 AM ET
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer鈥檚 disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.
| 听 | 听 |
| Event details: | |
| 听 | 听 |
| Date: | Thursday, November 7th |
| Time: | 8:30 a.m. Eastern Time |
| Audio Webcast: | |
| Or | |
| Audio Webcast: | https://edge.media-server.com/mmc/p/tzb9j3sy |
| 听 | 听 |
A replay of the audio webcast will also be available on the 鈥淐ompany Presentations鈥� page of the Cassava Sciences website for 90 days following the webcast.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer鈥檚 disease.
Simufilam is Cassava Sciences鈥� small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain.听Cassava Sciences believes that simufilam interrupts amyloid-尾42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.
For more information, please visit:
For More Information Contact:
Investors
Sandya van der Weid
Media
Sitrick And Company
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
FAQ
When will Cassava Sciences (SAVA) report Q3 2024 earnings?
How can I access Cassava Sciences (SAVA) Q3 2024 earnings call?
How long will Cassava Sciences (SAVA) Q3 2024 earnings call replay be available?
